Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hirata, A.
Right arrow Articles by Ono, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hirata, A.
Right arrow Articles by Ono, M.
[Cancer Research 62, 2554-2560, May 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

ZD1839 (Iressa) Induces Antiangiogenic Effects through Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase1

Akira Hirata, Soh-ichiro Ogawa, Takuro Kometani, Takashi Kuwano, Seiji Naito, Michihiko Kuwano and Mayumi Ono2

Departments of Medical Biochemistry [A. H., S. O., To. K., Ta. K., M. K., M. O.] and Urology [S. N.], Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

Epidermal growth factor receptor (EGFR) tyrosine kinase is a potential target for anticancer therapy. ZD1839 (Iressa) is a selective inhibitor of EGFR tyrosinekinase. In this study, we investigated the question as to whether the antitumor effect of ZD1839 is partly attributable to antiangiogenic activity and the potential mechanisms involved. Both ZD1839 and SU5416 [a vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor] inhibited the migration of human umbilical vein endothelial cell cocultivated with EGF-stimulated cancer cells. ZD1839 also inhibited EGF-induced migration and the formation of tube-like structures by human microvascular endothelial cells. Moreover, ZD1839 almost completely blocked EGF-induced neovascularization of mice cornea, and SU5416 partially blocked neovascularization. In contrast, ZD1839 did not inhibit VEGF-induced angiogenesis. However, EGF-induced up-regulation of the angiogenic factors, VEGF and IL-8, was almost completely blocked by ZD1839. The antitumor effects of ZD1839 could, therefore, be mediated in part by the inhibition of tumor angiogenesis through direct effects on microvascular endothelial cells that express EGFR and also through reduced production of proangiogenic factors by tumor cells.




This article has been cited by other articles:


Home page
 The OncologistHome page
A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink
Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow
Oncologist, June 1, 2008; 13(6): 631 - 644.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Normanno and A. De Luca
Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?
J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837.
[Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis
The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
Oncologist, October 1, 2007; 12(10): 1183 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Zhu, X. Jia, G. Xiao, Y. Kang, N. C. Partridge, and L. Qin
IMPLICATIONS FOR OSTEOLYTIC BONE METASTASES
J. Biol. Chem., September 14, 2007; 282(37): 26656 - 26664.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sandler
Bevacizumab in Non Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4613s - 4616s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. O. Hanrahan and J. V. Heymach
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4617s - 4622s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Wu, A. Onn, T. Isobe, S. Itasaka, R. R. Langley, T. Shitani, K. Shibuya, R. Komaki, A. J. Ryan, I. J. Fidler, et al.
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Mol. Cancer Ther., February 1, 2007; 6(2): 471 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ono and M. Kuwano
Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sandler and R. Herbst
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Clin. Cancer Res., July 15, 2006; 12(14): 4421s - 4425s.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Zania, S. Kritikou, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou
Blockade of Angiogenesis by Small Molecule Antagonists to Protease-Activated Receptor-1: Association with Endothelial Cell Growth Suppression and Induction of Apoptosis
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 246 - 254.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano
Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis.
Cancer Res., June 15, 2006; 66(12): 6233 - 6242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-i. Ueda, Y. Basaki, M. Yoshie, K. Ogawa, S. Sakisaka, M. Kuwano, and M. Ono
PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib.
Cancer Res., May 15, 2006; 66(10): 5346 - 5353.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno and W. J Gullick
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Endocr. Relat. Cancer, March 1, 2006; 13(1): 3 - 6.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Maione, C. Gridelli, T. Troiani, and F. Ciardiello
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC.
Oncologist, March 1, 2006; 11(3): 274 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Hall, F. R. Westwood, and P. F. Wadsworth
Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate
Toxicol Pathol, February 1, 2006; 34(2): 131 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al.
Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice
Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Bozec, P. Formento, J. Ciccolini, R. Fanciullino, L. Padovani, X. Murraciole, J.-L. Fischel, and G. Milano
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation
Mol. Cancer Ther., December 1, 2005; 4(12): 1962 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E.W. Cohen, M. A. Kane, M. A. List, B. E. Brockstein, B. Mehrotra, D. Huo, A. M. Mauer, C. Pierce, A. Dekker, and E. E. Vokes
Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., December 1, 2005; 11(23): 8418 - 8424.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Taron, Y. Ichinose, R. Rosell, T. Mok, B. Massuti, L. Zamora, J. L. Mate, C. Manegold, M. Ono, C. Queralt, et al.
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
Clin. Cancer Res., August 15, 2005; 11(16): 5878 - 5885.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold, and W. L. Elliott
Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor
Mol. Cancer Ther., June 1, 2005; 4(6): 938 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono
HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells
Cancer Res., May 15, 2005; 65(10): 4253 - 4260.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Yokoi, P. H. Thaker, S. Yazici, R. R. Rebhun, D.-H. Nam, J. He, S.-J. Kim, J. L. Abbruzzese, S. R. Hamilton, and I. J. Fidler
Dual Inhibition of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Phosphorylation by AEE788 Reduces Growth and Metastasis of Human Colon Carcinoma in an Orthotopic Nude Mouse Model
Cancer Res., May 1, 2005; 65(9): 3716 - 3725.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Yoshimoto, K. Kasahara, M. Nishio, T. Hourai, T. Sone, H. Kimura, M. Fujimura, and S. Nakao
Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, D. H. Johnson, E. Mininberg, D. P. Carbone, T. Henderson, E. S. Kim, G. Blumenschein Jr, J. J. Lee, D. D. Liu, M. T. Truong, et al.
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2544 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers
AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives
Ann. Onc., February 1, 2005; 16(2): 189 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P M Harari
Epidermal growth factor receptor inhibition strategies in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. L. Matheson, J. P. McNamee, T. Wang, M. A. Alaoui-Jamali, A. M. Tari, and B. J. Jean-Claude
The Combi-Targeting Concept: Dissection of the Binary Mechanism of Action of the Combi-Triazene SMA41 in Vitro and Antitumor Activity in Vivo
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1163 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. H. Kim, G. Ishii, K. Goto, K. Nagai, K. Tsuta, S. Shiono, J. Nitadori, T. Kodama, Y. Nishiwaki, and A. Ochiai
Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung
Clin. Cancer Res., November 1, 2004; 10(21): 7311 - 7317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. P. J. Leenders, B. Kusters, K. Verrijp, C. Maass, P. Wesseling, A. Heerschap, D. Ruiter, A. Ryan, and R. de Waal
Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option
Clin. Cancer Res., September 15, 2004; 10(18): 6222 - 6230.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Lin, S.-C. Tsai, C.-C. Lee, B.-W. Wang, J.-Y. Liou, and K.-G. Shyu
Berberine Inhibits HIF-1{alpha} Expression via Enhanced Proteolysis
Mol. Pharmacol., September 1, 2004; 66(3): 612 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S.-i. Ueda, H. Kinoshita, T. Fujii, and M. Kuwano
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
Mol. Cancer Ther., April 1, 2004; 3(4): 465 - 472.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
T. KUWANO, S. NAKAO, H. YAMAMOTO, M. TSUNEYOSHI, T. YAMAMOTO, M. KUWANO, and M. ONO
Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis
FASEB J, February 1, 2004; 18(2): 300 - 310.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ramesh, A. M. Mhashilkar, F. Tanaka, Y. Saito, C. D. Branch, K. Sieger, J. B. Mumm, A. L. Stewart, A. Boquio, L. Dumoutier, et al.
Melanoma Differentiation-associated Gene 7/Interleukin (IL)-24 Is a Novel Ligand That Regulates Angiogenesis via the IL-22 Receptor
Cancer Res., August 15, 2003; 63(16): 5105 - 5113.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Matsuo, H. Sakurai, and I. Saiki
ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Shows Antimetastatic Activity Using a Hepatocellular Carcinoma Model
Mol. Cancer Ther., June 1, 2003; 2(6): 557 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone
Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways
Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Nakao, T. Kuwano, T. Ishibashi, M. Kuwano, and M. Ono
Synergistic Effect of TNF-{alpha} in Soluble VCAM-1-Induced Angiogenesis Through {alpha}4 Integrins
J. Immunol., June 1, 2003; 170(11): 5704 - 5711.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. Brat and T. B. Mapstone
Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression
Ann Intern Med, April 15, 2003; 138(8): 659 - 668.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler
Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice
Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Nahta, G. N. Hortobagyi, and F. J. Esteva
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Oncologist, February 1, 2003; 8(1): 5 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. O'Reilly
Targeting Multiple Biological Pathways as a Strategy to Improve the Treatment of Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3309 - 3310.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Ieki, E. Saitoh, and M. Shibuya
Acute lung injury as a possible adverse drug reaction related to gefitinib
Eur. Respir. J., January 1, 2002; 22(1): 179 - 181.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.